Home › NDC Lookup › RxCUI directory › RxCUI 2168542

Tafamidis meglumine 20 MG Oral Capsule — RxCUI 2168542

RxNorm drug concept · Semantic clinical drug
RxCUI 2168542 Semantic clinical drug · SCD ● Current RxNorm concept 2 FDA products 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2168542
Official nameTafamidis meglumine 20 MG Oral Capsule
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known astafamidis meglumine 20 MG (equivalent to tafamidis 12.2 MG) Oral Tablet
FDA products mapped2
Package NDCs mapped2
Reported Medicaid activity (SDUD)753 prescriptions · 12 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Tafamidis: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • ATTR-CM stands for transthyretin-mediated amyloid cardiomyopathy — a condition where a protein in your blood called transthyretin (TTR) becomes unstable, breaks apart, and builds u...
  • What exactly is ATTR-CM, and why do I need this medication?
  • They both contain tafamidis and are approved for the same condition, but they are not interchangeable on a milligram-for-milligram basis — meaning you can't simply swap one for the...
  • I've been prescribed Vyndamax. Is that the same as Vyndaqel?
📖 Read our full Tafamidis guide →

🕸️ Concept Web — How Tafamidis meglumine 20 MG Oral Capsule Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Tafamidis meglumine 20 MG Oral Capsule RxCUI 2168542

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Tafamidis 1545063
    • Tafamidis meglumine 1727003
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Vyndaqel 2168543
  3. Dose forms 13

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Tafamidis Oral Capsule 1545067
    • Tafamidis meglumine Oral Capsule 2645649
    • Tafamidis Oral Product 1545065
    • Tafamidis Pill 1545066
    • Tafamidis meglumine Oral Product 2659115
    • Tafamidis meglumine Pill 2661662
    • Tafamidis Oral Capsule [Vyndaqel] 2168545
    • Tafamidis meglumine Oral Capsule [Vyndaqel] 2657706
    • +5 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 19 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Tafamidis meglumine 20 MG SCDC · 2168541
  • Tafamidis Oral Capsule SCDF · 1545067
  • Tafamidis meglumine Oral Capsule SCDFP · 2645649
  • Tafamidis Oral Product SCDG · 1545065
  • Tafamidis Pill SCDG · 1545066
  • Tafamidis meglumine Oral Product SCDGP · 2659115
  • Tafamidis meglumine Pill SCDGP · 2661662

Brand-Name Concepts

  • Tafamidis meglumine 20 MG Oral Capsule [Vyndaqel] SBD · 2168548
  • Tafamidis meglumine 20 MG [Vyndaqel] SBDC · 2168544
  • Tafamidis Oral Capsule [Vyndaqel] SBDF · 2168545
  • Tafamidis meglumine Oral Capsule [Vyndaqel] SBDFP · 2657706
  • Vyndaqel Oral Product SBDG · 2168546
  • Vyndaqel Pill SBDG · 2168547
  • Vyndaqel BN · 2168543

📦 FDA Products & Package NDCs

2 products · 2 package NDCs
2 package NDCs map to RxCUI 2168542 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00069-1975-40 4 CARTON in 1 CARTON (0069-1975-40) / 30 BLISTER PACK in 1... Vyndaqel Pfizer Laboratories Div Pfizer Inc 2019-05-16
00069-8730-30 30 BLISTER PACK in 1 CARTON (0069-8730-30) / 1 CAPSULE, LIQ... Vyndamax Pfizer Laboratories Div Pfizer Inc 2019-08-27
Observed labelers: Pfizer Laboratories Div Pfizer Inc (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.